Monica Raimo
Director of Product & Process Development Glycostem
Monica Raimo is a Senior R&D manager at Glycostem Therapeutics, which she joined in 2018. In her role, she oversees process development for Natural Killer cell therapies, as well as the development of clinically compliant genetic modified strategies, and how to leverage “omics” studies for the generation of cell therapies.
Before joining Glycostem, she was a scientist at InteRNA Technologies, working in the development of non-coding RNA therapeutics. Previously, she obtained a PhD in Molecular Oncology from the University of Turin, Italy, understanding the molecular mechanisms driving metastatic progression of melanoma and breast cancer. Raimo has contributed to patent applications in the field of stem and NK cell ex vivo culture and genetic engineering, and has published scientific articles in the field of cancer biology and immunology, non-coding RNAs, NK cell therapies and bioinformatics.
Seminars
Advancing cell and gene therapies from preclinical to clinical stages requires tackling critical manufacturing hurdles. Donor variability, cryopreservation, scalability, and equipment choices, including the use of bioreactors, all impact product quality, reproducibility, and regulatory readiness. This workshop explores practical strategies to strengthen manufacturing systems, mitigate risk, and ensure a smooth transition into the clinic.
Join this workshop to:
- Understand how donor variability and cryopreservation affect product quality, and ways to reduce these risks
- Explore scalability, bioreactor implementation, and equipment decisions that drive consistency and compliance
- Review case-based approaches for moving from preclinical data to robust clinical programs
